Site search

Clear filter
2818 results for '' found
Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM) – the FRAIL-M study (ACTRN12619001199101)
/
Fludrocortisone administration in aneurysmal subarachnoid haemorrhage (NCT06409364)
Fludrocortisone administration in aneurysmal subarachnoid haemorrhage (NCT06409364)
/
Accelerated Flap Coverage Versus Standard Timing in the Treatment of Severe Lower Extremity Musculoskeletal Injuries (NCT06293469)
Accelerated Flap Coverage Versus Standard Timing in the Treatment of Severe Lower Extremity Musculoskeletal Injuries (NCT06293469)
/
A Double- Blinded Placebo Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced/ Metastatic Her 2 Negative and Oestrogen Receptor Positive (ER+) Breast Ca
A Double- Blinded Placebo Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced/ Metastatic Her 2 Negative and Oestrogen Receptor Positive (ER+) Breast Ca
/
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis (NCT02914535)
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis (NCT02914535)
/
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis [IPF] and progressive pulmonary fibrosis [PPF] [FIBRON
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis [IPF] and progressive pulmonary fibrosis [PPF] [FIBRON
/
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-
/
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) (NCT05321069)
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) (NCT05321069)
/
Fibrinogen Early in Severe Trauma StudY II (NCT05449834)
Fibrinogen Early in Severe Trauma StudY II (NCT05449834)
/
Evaluating a telehealth exercise model of care for adults with CF: A feasibility randomised controlled trial (ACTRN12625000116426)
Evaluating a telehealth exercise model of care for adults with CF: A feasibility randomised controlled trial (ACTRN12625000116426)
/
35 36 37 38 39